Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis.
BACKGROUND
An epidemic of aseptic peritonitis related to the presence of peptidoglycan contaminant in some batches of icodextrin solution (Extraneal, Baxter Healthcare Corporation) occurred in Europe in the first six months of 2002.


METHODS
By case-control study we examined the clinical and biologic features of 5 patients with icodextrin-induced peritonitis (group AP) and compared them with 7 patients with bacterial peritonitis (group BP) recruited in our clinical center between January and June 2002.


RESULTS
Diagnosis of icodextrin-induced peritonitis was confirmed in all cases by a positive reintroduction test with contaminated batches of icodextrin. No recurrence was observed on re-exposure to icodextrin free of peptidoglycan. Skin tests were positive with contaminated icodextrin in 2 of 5 patients, while they were negative with icodextrin solution free of peptidoglycan (<0.6 ng/mL). During peritonitis, serum level of C-reactive protein (CRP) was lower in group AP (42.4 +/- 34 mg/L) than in group BP (135 +/- 59 mg/L) (P= 0.01). Leukocyte number in peritoneal dialysis effluent was lower in group AP (284 +/- 101/mm3), with a lower neutrophil/monocyte ratio (N/M = 0.67) than in group BP (1410 +/- 973/mm3; N/M = 4) (P < 0.05). A low number of peritoneal fluid eosinophilia (11 +/- 8%) was detected in group AP.


CONCLUSIONS
Icodextrin-induced peritonitis was associated with a burst of intraperitoneal cytokines. The phenotype of peritoneal neutrophils was different between aseptic and bacterial peritonitis, indicating that inflammatory stimuli that activate neutrophils in both types of peritonitis are clearly distinct. Finally, peritoneal injury measured by weight gain, peritoneal permeability, and CA125 concentration seemed to be less severe during icodextrin-induced peritonitis than during bacterial peritonitis.
Touré
Fatouma
F
Department of Nephrology, University Hospital of Reims, France.
Lavaud
Sylvie
S
Mohajer
Mehdi
M
Lavaud
François
F
Canivet
Eric
E
Nguyen
Philippe
P
Chanard
Jacques
J
Rieu
Philippe
P
D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000276:immunology*; D016022:Case-Control Studies; D016207:Cytokines / Q000378:metabolism; D015314:Dialysis Solutions / Q000009:adverse effects*; D005260:Female; D005936:Glucans / Q000009:adverse effects* / Q000276:immunology; D005947:Glucose / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018375:Neutrophil Activation; D010457:Peptidoglycan / Q000276:immunology; D010530:Peritoneal Dialysis; D010538:Peritonitis / Q000139:chemically induced* / Q000276:immunology / Q000382:microbiology
D016207:Cytokines; D015314:Dialysis Solutions; D005936:Glucans; D010457:Peptidoglycan; D000077607:Icodextrin; D005947:Glucose